> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Alcon Pulls CyPass Micro-Stent from Market
- URL: https://www.fdaweb.com/alcon-pulls-cypass-micro-stent-from-market/
- Published: 2018-08-31T12:00:00.000Z
- Updated: 2026-09-15T00:29:24.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5142242

Alcon has withdrawn from the market its CyPass Micro-Stent for surgical glaucoma due to safety concerns documented in a five-year study. The COMPASS-XT study showed that at five years, the *CyPass Micro-Stent* group experienced statistically significant endothelial cell loss compared to the group who underwent cataract surgery alone, an FDA [notice says](https://www.fda.gov/Safety/Recalls/ucm619109.htm?utm%5Fcampaign=Alcon%20Announces%20Voluntary%20Global%20Market%20Withdrawal%20of%20CyPass%20Micro-Stent%20for%20Surgical%20Glaucoma&utm%5Fmedium=email&utm%5Fsource=Eloqua). Alcon advises ophthalmic surgeons to stop implanting the device. The agency approved it in 2016 for use in conjunction with cataract surgery in adult patients with mild-to-moderate primary open-angle glaucoma.